Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Get Free Report) Director Bruce Cozadd sold 68,808 shares of the stock in a transaction dated Friday, November 6th. The stock was sold at an average price of $235.95, for a total value of $16,235,247.60. Following the sale, the director owned 357,567 shares of the company’s stock, valued at $84,367,933.65. This represents a 16.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Jazz Pharmaceuticals Price Performance
NASDAQ JAZZ traded up $1.89 during trading hours on Tuesday, reaching $245.43. The company’s stock had a trading volume of 576,689 shares, compared to its average volume of 931,379. Jazz Pharmaceuticals PLC has a 1 year low of $132.10 and a 1 year high of $266.38. The firm’s 50-day moving average price is $229.37 and its 200-day moving average price is $218.11. The company has a quick ratio of 1.58, a current ratio of 1.82 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $15.75 billion, a price-to-earnings ratio of 83.48, a PEG ratio of 0.47 and a beta of 0.38.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last issued its earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.03) by $0.15. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.21 billion. During the same quarter in the prior year, the business earned $8.13 earnings per share. Jazz Pharmaceuticals’s revenue for the quarter was up 10.4% on a year-over-year basis. On average, equities research analysts predict that Jazz Pharmaceuticals PLC will post 11.08 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on JAZZ shares. UBS Group increased their price target on Jazz Pharmaceuticals from $315.00 to $337.00 and gave the company a “buy” rating in a research note on Friday, September 11th. Stifel Nicolaus set a $275.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 4th. Piper Sandler boosted their target price on shares of Jazz Pharmaceuticals from $301.00 to $310.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Weiss Ratings cut shares of Jazz Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, October 28th. Finally, Wells Fargo & Company increased their price target on shares of Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $293.00.
Check Out Our Latest Analysis on JAZZ
Hedge Funds Weigh In On Jazz Pharmaceuticals
Large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp raised its position in Jazz Pharmaceuticals by 44.5% in the 1st quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock worth $317,485,000 after purchasing an additional 517,514 shares during the period. Bank of America Corp DE boosted its position in shares of Jazz Pharmaceuticals by 10.9% during the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after buying an additional 99,656 shares during the period. Systematic Financial Management LP boosted its position in shares of Jazz Pharmaceuticals by 2.6% during the first quarter. Systematic Financial Management LP now owns 407,114 shares of the specialty pharmaceutical company’s stock valued at $76,965,000 after buying an additional 10,237 shares during the period. Retirement Systems of Alabama grew its stake in shares of Jazz Pharmaceuticals by 7.6% during the third quarter. Retirement Systems of Alabama now owns 171,801 shares of the specialty pharmaceutical company’s stock valued at $39,775,000 after buying an additional 12,138 shares during the last quarter. Finally, Quantinno Capital Management LP grew its stake in shares of Jazz Pharmaceuticals by 9.7% during the first quarter. Quantinno Capital Management LP now owns 191,286 shares of the specialty pharmaceutical company’s stock valued at $36,163,000 after buying an additional 16,928 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.
Read More
- Five stocks we like better than Jazz Pharmaceuticals
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
